Analysis of Thyroid Tumorigenesis in Xenograft Mouse Model
Analysis of thyroid tumorigenesis in xenograft mouse model is important to study human thyroid cancer. Recent studies have made big strides toward understanding the molecular mechanisms by which thyroid hormone nuclear receptors (TR) act to maintain normal cellular functions in growth, differentiation, and development. Despite growing interest, the role of TR in oncogenesis remains to be fully elucidated. Two TR genes give rise to three major TR isoforms: TRα1, TRβ1, and TRβ2. These TR subtypes express in a tissue- and development-dependent manner. Research has been directed at understanding the mechanisms by which TR could mediate aberrant cellular signaling that contributes to oncogenesis, at dissecting possible distinct roles of TR isoforms in oncogenesis, and at the differential susceptibility of target tissues to the oncogenic actions of TR. This chapter gives a brief overview of the current undersatanding of known molecular oncogenic actions of TR. Here, we describe analysis of thyroid tumorigenesis used in interrogating the in vivo oncogenic actions of TR.
Key wordsThyroid hormone receptor Oncogenesis Thyroid tumorigenesis
We regret any reference omissions due to length limitation. We wish to thank all colleagues and collaborators who have contributed to the work described in this review. The research described in this review by the authors and their colleagues at National Cancer Institute was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.
- 8.Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2(3):283–287PubMedGoogle Scholar
- 9.Dayton AI, Selden JR, Laws G, Dorney DJ, Finan J, Tripputi P, Emanuel BS, Rovera G, Nowell PC, Croce CM (1984) A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 81(14):4495–4499CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Yen PM, Ikeda M, Wilcox EC, Brubaker JH, Spanjaard RA, Sugawara A, Chin WW (1994) Half-site arrangement of hybrid glucocorticoid and thyroid hormone response elements specifies thyroid hormone receptor complex binding to DNA and transcriptional activity. J Biol Chem 269(17):12704–12709PubMedGoogle Scholar
- 19.Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S, Weintraub B, Willingham MC, Barlow C, Cheng S (2000) Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A 97(24):13209–13214. https://doi.org/10.1073/pnas.230285997 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, Willingham MC, Cheng SY (2006) Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 116(11):2972–2984. https://doi.org/10.1172/JCI28598 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY (2012) SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res 18(5):1281–1290. https://doi.org/10.1158/1078-0432.CCR-11-2892 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Araki O, Ying H, Furuya F, Zhu X, Cheng SY (2005) Thyroid hormone receptor beta mutants: dominant negative regulators of peroxisome proliferator-activated receptor gamma action. Proc Natl Acad Sci U S A 102(45):16251–16256. https://doi.org/10.1073/pnas.0508556102 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Kim CS, Furuya F, Ying H, Kato Y, Hanover JA, Cheng SY (2007) Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer. Endocrinology 148(3):1306–1312. https://doi.org/10.1210/en.2006-0923 CrossRefPubMedGoogle Scholar
- 36.Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS, Willingham MC, Cheng SY (2005) An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25(1):124–135. https://doi.org/10.1128/MCB.25.1.124-135.2005 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD (1991) Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest 88(6):2123–2130. https://doi.org/10.1172/JCI115542 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Figueira AC, Saidemberg DM, Souza PC, Martinez L, Scanlan TS, Baxter JD, Skaf MS, Palma MS, Webb P, Polikarpov I (2011) Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange. Mol Endocrinol 25(1):15–31. https://doi.org/10.1210/me.2010-0202 CrossRefPubMedGoogle Scholar
- 41.Wu SY, Cohen RN, Simsek E, Senses DA, Yar NE, Grasberger H, Noel J, Refetoff S, Weiss RE (2006) A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 91(5):1887–1895. https://doi.org/10.1210/jc.2005-2428 CrossRefPubMedGoogle Scholar